A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This feasibility trial studies how well daratumumab in combination with dose-adjusted
etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride
(DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma.
Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a
monoclonal antibody that specifically targets CD38 expressing cells, and may help the body?s
immune system attack the cancer and interfere with the ability of cancer cells to grow and
spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate,
cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving daratumumab may enhance the effectiveness of a standard
chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.
Phase:
Early Phase 1
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
AIDS and Cancer Specimen Resource Janssen Scientific Affairs, LLC Memorial Sloan Kettering Cancer Center Montefiore Medical Center National Cancer Institute (NCI) The Emmes Company, LLC